International – ICH M13A BE testing guideline expected to be adopted this summer
The International Council for Harmonisation (ICH) is expected to adopt its M13A guideline on bioequivalence (BE) testing of immediate-release (IR) solid oral dosage form...
USA – FDA launches new clinical trial center to improve innovation, communication
The US Food and Drug Administration’s (FDA) Center for Drug Evaluation and Research (CDER) has launched a new center for internal and external experts...
Europe – Parliament adopts its position on EU pharmaceutical reform
The legislative package, covering medicinal products for human use, consists of a new directive (adopted with 495 votes in favour, 57 against and 45...
Europe – Reflection papers on regulatory requirements for the development of medicinal products for...
The drafting of a reflection paper on regulatory requirements for the development of medicinal products for chronic non-infectious liver diseases (PBC, PSC, NASH) is intended in order to...
USA – Clinical Pharmacology Considerations for Antibody-Drug Conjugates – Final Guidance for Industry
FDA published the final guidance for industry, Clinical Pharmacology Considerations for Antibody-Drug Conjugates, and recently published accompaniments to the guidance document:
France – Expérimentation du cannabis médical : quelle continuité de la prise en charge...
Le Décret n° 2024-259 du 23 mars 2024 modifiant le décret n° 2020-1230 du 7 octobre 2020 relatif à l'expérimentation de l'usage médical du cannabis et...
USA – Data Integrity for In Vivo Bioavailability and Bioequivalence Studies: Guidance for Industry
The purpose of this guidance is to provide recommendations to applicants and testing site
management on achieving and maintaining data integrity for the clinical and...
USA – Center for Drug Evaluation and Research – Office of Pharmaceutical Quality :...
FDA’s Office of Office of Pharmaceutical Quality (OPQ) published its 2023 Annual Report, which details the many ways OPQ assures the availability, safety, and...
USA – Study: Few FDA-approved targeted cancer drugs meet ESMO benefit benchmarks
Fewer than one-third of molecularly targeted cancer drugs recently approved by the US Food and Drug Administration (FDA) meet established European benchmarks for clinical...
USA – FDA turns attention to data integrity lapses at testing sites in new...
The US Food and Drug Administration (FDA) has issued a draft guidance outlining how manufacturers can ensure the data integrity of bioavailability (BA) and...
